Having trouble accessing articles? Reset your cache.

Tarextumab: Completed Phase Ib/II enrollment

OncoMed completed enrollment of 145 patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled,

Read the full 187 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE